We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Keryx Biopharmaceuticals, Inc. (delisted) | NASDAQ:KERX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.36 | 3.10 | 3.35 | 0 | 01:00:00 |
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
13-4087132
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Large accelerated filer
|
|
x
|
Accelerated filer
|
|
¨
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
|
¨
|
Emerging growth company
|
|
¨
|
|
|
|
|
|
Page
|
PART I
|
||
|
|
|
Item 1
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
Item 2
|
||
|
|
|
Item 3
|
||
|
|
|
Item 4
|
||
|
|
|
PART II
|
||
|
|
|
Item 1
|
||
|
|
|
Item 1A
|
||
|
|
|
Item 6
|
•
|
estimates regarding market size and projected growth, as well as our expectation of market acceptance of Auryxia
®
(ferric citrate), market share and product sales guidance;
|
•
|
expectations regarding the commercialization of Auryxia;
|
•
|
expectations regarding our ability to successfully develop and obtain U.S. Food and Drug Administration approval of Auryxia for the treatment of iron deficiency anemia in non-dialysis dependent chronic kidney disease patients;
|
•
|
expectations regarding our ability to identify a commercial partner(s) to launch Fexeric
®
(ferric citrate coordination complex) in the European market;
|
•
|
expectations for generating revenue, positive cash flow or becoming profitable on a sustained basis;
|
•
|
estimates of the sufficiency of our existing cash and cash equivalents to finance our operating requirements;
|
•
|
expected losses;
|
•
|
expectations for future capital requirements;
|
•
|
expectations for increases or decreases in expenses;
|
•
|
expectations for pre-clinical and clinical development and regulatory progress, including manufacturing, commercialization and reimbursement (including market acceptance) of ferric citrate or any other products that we may acquire or in-license;
|
•
|
expectations for incurring capital expenditures to expand our development and manufacturing capabilities;
|
•
|
expectations regarding our ability to successfully market Riona
®
through our Japanese partner, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd.;
|
•
|
expectations of the scope of patent protection with respect to Auryxia, Fexeric and Riona;
|
•
|
expectations or ability to enter into marketing and other partnership agreements; and
|
•
|
expectations or ability to enter into product acquisition and in-licensing transactions.
|
|
June 30, 2017
|
|
December 31, 2016
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
140,527
|
|
|
$
|
111,810
|
|
Inventory
|
18,085
|
|
|
12,681
|
|
||
Accounts receivable, net
|
8,459
|
|
|
5,236
|
|
||
Other current assets
|
8,636
|
|
|
3,170
|
|
||
Total current assets
|
175,707
|
|
|
132,897
|
|
||
Property, plant and equipment, net
|
4,172
|
|
|
4,211
|
|
||
Goodwill
|
3,208
|
|
|
3,208
|
|
||
Other assets, net
|
1,102
|
|
|
1,111
|
|
||
Total assets
|
$
|
184,189
|
|
|
$
|
141,427
|
|
Liabilities and stockholders’ equity (deficit)
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable and accrued expenses
|
$
|
30,146
|
|
|
$
|
21,190
|
|
Deferred lease incentive, current portion
|
244
|
|
|
244
|
|
||
Other current liabilities
|
131
|
|
|
117
|
|
||
Total current liabilities
|
30,521
|
|
|
21,551
|
|
||
Convertible senior notes
|
125,000
|
|
|
125,000
|
|
||
Deferred lease incentive, net of current portion
|
1,140
|
|
|
1,262
|
|
||
Deferred tax liability
|
909
|
|
|
870
|
|
||
Other liabilities
|
970
|
|
|
1,040
|
|
||
Total liabilities
|
158,540
|
|
|
149,723
|
|
||
Commitments and contingencies
|
|
|
|
||||
Stockholders’ equity (deficit):
|
|
|
|
||||
Preferred stock, $0.001 par value per share (5,000,000 shares authorized, no shares issued and outstanding)
|
—
|
|
|
—
|
|
||
Common stock, $0.001 par value per share (230,000,000 and 180,000,000 shares authorized, 118,584,256 and 105,921,052 shares issued, 118,504,308 and 105,841,104 shares outstanding at June 30, 2017 and December 31, 2016, respectively)
|
119
|
|
|
106
|
|
||
Additional paid-in capital
|
970,498
|
|
|
827,053
|
|
||
Treasury stock, at cost, 79,948 shares
|
(357
|
)
|
|
(357
|
)
|
||
Accumulated deficit
|
(944,611
|
)
|
|
(835,098
|
)
|
||
Total stockholders’ equity (deficit)
|
25,649
|
|
|
(8,296
|
)
|
||
Total liabilities and stockholders’ equity (deficit)
|
$
|
184,189
|
|
|
$
|
141,427
|
|
|
Three months ended
June 30, |
|
Six months ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Revenues:
|
|
|
|
|
|
|
|
||||||||
Net U.S. Auryxia product sales
|
$
|
14,116
|
|
|
$
|
8,279
|
|
|
$
|
24,621
|
|
|
$
|
13,895
|
|
License revenue
|
1,028
|
|
|
1,009
|
|
|
2,343
|
|
|
2,218
|
|
||||
Total revenues
|
15,144
|
|
|
9,288
|
|
|
26,964
|
|
|
16,113
|
|
||||
Costs and expenses:
|
|
|
|
|
|
|
|
||||||||
Cost of goods sold
|
4,379
|
|
|
5,099
|
|
|
8,653
|
|
|
6,170
|
|
||||
License expenses
|
617
|
|
|
605
|
|
|
1,406
|
|
|
1,331
|
|
||||
Research and development
|
9,012
|
|
|
7,029
|
|
|
15,776
|
|
|
14,645
|
|
||||
Selling, general and administrative
|
24,986
|
|
|
20,188
|
|
|
48,089
|
|
|
40,997
|
|
||||
Total costs and expenses
|
38,994
|
|
|
32,921
|
|
|
73,924
|
|
|
63,143
|
|
||||
Operating loss
|
(23,850
|
)
|
|
(23,633
|
)
|
|
(46,960
|
)
|
|
(47,030
|
)
|
||||
Other income (expense):
|
|
|
|
|
|
|
|
||||||||
Amortization of debt discount
|
(62,965
|
)
|
|
(18,479
|
)
|
|
(62,965
|
)
|
|
(34,226
|
)
|
||||
Other income (expense), net
|
338
|
|
|
(2,519
|
)
|
|
452
|
|
|
(4,319
|
)
|
||||
Total other income (expense)
|
(62,627
|
)
|
|
(20,998
|
)
|
|
(62,513
|
)
|
|
(38,545
|
)
|
||||
Loss before income taxes
|
(86,477
|
)
|
|
(44,631
|
)
|
|
(109,473
|
)
|
|
(85,575
|
)
|
||||
Income taxes
|
20
|
|
|
20
|
|
|
40
|
|
|
40
|
|
||||
Net loss
|
$
|
(86,497
|
)
|
|
$
|
(44,651
|
)
|
|
$
|
(109,513
|
)
|
|
$
|
(85,615
|
)
|
Basic and diluted net loss per common share
|
$
|
(0.77
|
)
|
|
$
|
(0.42
|
)
|
|
$
|
(1.00
|
)
|
|
$
|
(0.81
|
)
|
Weighted average shares used in computing basic and diluted net loss per common share
|
112,590,188
|
|
|
105,842,030
|
|
|
109,846,152
|
|
|
105,745,800
|
|
|
Six months ended
June 30, |
||||||
|
2017
|
|
2016
|
||||
Cash flows from operating activities
|
|
|
|
||||
Net loss
|
$
|
(109,513
|
)
|
|
$
|
(85,615
|
)
|
Adjustments to reconcile loss to cash flows used in operating activities:
|
|
|
|
||||
Stock-based compensation expense
|
7,336
|
|
|
6,846
|
|
||
Amortization of debt discount
|
62,965
|
|
|
34,226
|
|
||
Change in fair value of derivative liability
|
(225
|
)
|
|
4,718
|
|
||
Depreciation and amortization
|
459
|
|
|
520
|
|
||
Amortization of deferred lease incentive
|
(122
|
)
|
|
(122
|
)
|
||
Write-down of inventory to net realizable value
|
335
|
|
|
2,736
|
|
||
Cash received from landlord
|
—
|
|
|
637
|
|
||
Deferred income taxes
|
39
|
|
|
40
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Other current assets
|
(5,466
|
)
|
|
754
|
|
||
Accounts receivable, net
|
(3,223
|
)
|
|
(1,445
|
)
|
||
Inventory
|
(4,683
|
)
|
|
(3,808
|
)
|
||
Other assets
|
9
|
|
|
—
|
|
||
Other current liabilities
|
14
|
|
|
(340
|
)
|
||
Accounts payable and accrued expenses
|
7,988
|
|
|
(1,735
|
)
|
||
Deferred revenue
|
—
|
|
|
(168
|
)
|
||
Other liabilities
|
(70
|
)
|
|
158
|
|
||
Net cash used in operating activities
|
(44,157
|
)
|
|
(42,598
|
)
|
||
Cash flows from investing activities
|
|
|
|
||||
Purchases of property, plant and equipment
|
(420
|
)
|
|
(2,040
|
)
|
||
Net cash used in investing activities
|
(420
|
)
|
|
(2,040
|
)
|
||
Cash flows from financing activities
|
|
|
|
||||
Proceeds from issuance of common stock, net of commission
|
73,125
|
|
|
—
|
|
||
Payments for common stock issuance costs
|
(88
|
)
|
|
—
|
|
||
Proceeds from exercise of stock options
|
257
|
|
|
144
|
|
||
Net cash provided by financing activities
|
73,294
|
|
|
144
|
|
||
Net increase (decrease) in cash and cash equivalents
|
28,717
|
|
|
(44,494
|
)
|
||
Cash and cash equivalents at beginning of the period
|
111,810
|
|
|
200,290
|
|
||
Cash and cash equivalents at end of the period
|
$
|
140,527
|
|
|
$
|
155,796
|
|
Non-cash financing activities:
|
|
|
|
||||
Reclassification of derivative liability to equity
|
$
|
62,735
|
|
|
$
|
51,404
|
|
|
(in thousands)
|
Three months ended
June 30, 2017 |
|
Percent of gross
Auryxia
product sales
|
|
Three months ended
June 30, 2016 |
|
Percent of gross
Auryxia
product sales
|
||||||
Gross Auryxia product sales
|
$
|
26,029
|
|
|
|
|
$
|
12,561
|
|
|
|
||
Less provision for product sales allowances and accruals:
|
|
|
|
|
|
|
|
||||||
Trade allowances
|
2,463
|
|
|
9
|
%
|
|
1,555
|
|
|
12
|
%
|
||
Rebates, chargebacks and discounts
|
8,784
|
|
|
34
|
%
|
|
2,543
|
|
|
20
|
%
|
||
Product returns
|
346
|
|
|
2
|
%
|
|
—
|
|
|
—
|
|
||
Other incentives
(1)
|
320
|
|
|
1
|
%
|
|
184
|
|
|
2
|
%
|
||
Total
|
11,913
|
|
|
46
|
%
|
|
4,282
|
|
|
34
|
%
|
||
Net U.S. Auryxia product sales
|
$
|
14,116
|
|
|
|
|
$
|
8,279
|
|
|
|
(1)
|
Includes co-pay assistance and voucher rebates.
|
(in thousands)
|
Six months ended June 30, 2017
|
|
Percent of gross
Auryxia product sales |
|
Six months ended June 30, 2016
|
|
Percent of gross
Auryxia product sales |
||||||
Gross Auryxia product sales
|
$
|
43,983
|
|
|
|
|
$
|
21,185
|
|
|
|
||
Less provision for product sales allowances and accruals
|
|
|
|
|
|
|
|
||||||
Trade allowances
|
4,228
|
|
|
9
|
%
|
|
2,701
|
|
|
13
|
%
|
||
Rebates, chargebacks and discounts
|
14,114
|
|
|
32
|
%
|
|
4,221
|
|
|
20
|
%
|
||
Product returns
|
278
|
|
|
1
|
%
|
|
—
|
|
|
—
|
|
||
Other incentives
(1)
|
742
|
|
|
2
|
%
|
|
368
|
|
|
1
|
%
|
||
Total
|
19,362
|
|
|
44
|
%
|
|
7,290
|
|
|
34
|
%
|
||
Net U.S. Auryxia product sales
|
$
|
24,621
|
|
|
|
|
$
|
13,895
|
|
|
|
(1)
|
Includes co-pay assistance and voucher rebates.
|
(in thousands)
|
June 30, 2017
|
|
June 30, 2016
|
||
Options to purchase common stock
|
12,469
|
|
|
8,869
|
|
Shares issuable upon conversion of convertible senior notes
|
33,422
|
|
|
33,422
|
|
|
45,891
|
|
|
42,291
|
|
|
June 30, 2017
|
|
December 31, 2016
|
||
Fresenius Medical Care Rx
|
23
|
%
|
|
22
|
%
|
AmerisourceBergen Drug Corporation
|
22
|
%
|
|
23
|
%
|
Cardinal Health, Inc.
|
20
|
%
|
|
11
|
%
|
DaVita Rx
|
16
|
%
|
|
10
|
%
|
McKesson Corporation
|
14
|
%
|
|
31
|
%
|
|
Financial assets at fair value
as of June 30, 2017 |
|
Financial assets at fair value
as of December 31, 2016 |
||||||||||||||||||||
(in thousands)
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cash equivalents
(1)
|
$
|
34,373
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
107,084
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Total assets
|
$
|
34,373
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
107,084
|
|
|
$
|
—
|
|
|
$
|
—
|
|
(1)
|
Cash equivalents as of June 30, 2017 and December 31, 2016 consisted of institutional money market funds. The carrying value of our money market funds approximates fair value due to their short-term maturities.
|
(in thousands)
|
June 30, 2017
|
|
December 31, 2016
|
||||
Raw materials
|
$
|
596
|
|
|
$
|
418
|
|
Work in process
|
15,499
|
|
|
11,430
|
|
||
Finished goods
|
1,990
|
|
|
833
|
|
||
Total inventory
|
$
|
18,085
|
|
|
$
|
12,681
|
|
|
Number of shares
|
|
Weighted average exercise price
|
|||
Outstanding at December 31, 2016
|
8,677,998
|
|
|
$
|
7.28
|
|
Granted
|
4,409,150
|
|
|
5.39
|
|
|
Exercised
|
(62,802
|
)
|
|
4.09
|
|
|
Forfeited or Expired
|
(555,477
|
)
|
|
7.07
|
|
|
Outstanding at June 30, 2017
|
12,468,869
|
|
|
$
|
6.64
|
|
Vested and expected to vest at June 30, 2017
|
7,531,012
|
|
|
$
|
7.50
|
|
Exercisable at June 30, 2017
|
4,079,875
|
|
|
$
|
8.98
|
|
|
Number of shares
|
|
Weighted average grant date fair value
|
|||
Outstanding at December 31, 2016
|
1,524,884
|
|
|
$
|
7.07
|
|
Granted
|
1,116,275
|
|
|
5.66
|
|
|
Vested
|
(394,323
|
)
|
|
6.00
|
|
|
Forfeited
|
(90,193
|
)
|
|
5.47
|
|
|
Outstanding at June 30, 2017
|
2,156,643
|
|
|
$
|
6.61
|
|
|
Three months ended June 30,
|
|
Six months ended June 30,
|
||||||||||||
(in thousands)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Cost of goods sold
|
$
|
28
|
|
|
$
|
8
|
|
|
$
|
88
|
|
|
$
|
14
|
|
Research and development
|
483
|
|
|
880
|
|
|
1,061
|
|
|
1,585
|
|
||||
Selling, general and administrative
|
3,161
|
|
|
2,665
|
|
|
6,187
|
|
|
5,247
|
|
||||
Total stock-based compensation expense
|
$
|
3,672
|
|
|
$
|
3,553
|
|
|
$
|
7,336
|
|
|
$
|
6,846
|
|
(in thousands)
|
June 30, 2017
|
|
December 31, 2016
|
||||
Accounts payable
|
$
|
7,696
|
|
|
$
|
2,225
|
|
Accrued compensation and related liabilities
|
5,709
|
|
|
8,190
|
|
||
Professional, license, and other fees and expenses
|
6,374
|
|
|
6,159
|
|
||
Commercial rebates, fees and returns
|
10,367
|
|
|
4,616
|
|
||
Total accounts payable and accrued expenses
|
$
|
30,146
|
|
|
$
|
21,190
|
|
|
Three months ended June 30,
|
|
Six months ended June 30,
|
||||||||||||
(in thousands)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Interest income
|
$
|
118
|
|
|
$
|
185
|
|
|
$
|
235
|
|
|
$
|
387
|
|
Other income (expense)
|
(5
|
)
|
|
7
|
|
|
(8
|
)
|
|
12
|
|
||||
Fair value adjustment to derivative liability
|
225
|
|
|
(2,711
|
)
|
|
225
|
|
|
(4,718
|
)
|
||||
|
$
|
338
|
|
|
$
|
(2,519
|
)
|
|
$
|
452
|
|
|
$
|
(4,319
|
)
|
(in thousands)
|
Three months ended
June 30, 2017 |
|
Percent of gross
Auryxia
product sales
|
|
Three months ended
June 30, 2016 |
|
Percent of gross
Auryxia
product sales
|
||||||
Gross Auryxia product sales
|
$
|
26,029
|
|
|
|
|
$
|
12,561
|
|
|
|
||
Less provision for product sales allowances and accruals
|
|
|
|
|
|
|
|
||||||
Trade allowances
|
2,463
|
|
|
9
|
%
|
|
1,555
|
|
|
12
|
%
|
||
Rebates, chargebacks and discounts
|
8,784
|
|
|
34
|
%
|
|
2,543
|
|
|
20
|
%
|
||
Product returns
|
346
|
|
|
2
|
%
|
|
—
|
|
|
—
|
|
||
Other incentives
(1)
|
320
|
|
|
1
|
%
|
|
184
|
|
|
2
|
%
|
||
Total
|
11,913
|
|
|
46
|
%
|
|
4,282
|
|
|
34
|
%
|
||
Net U.S. Auryxia product sales
|
$
|
14,116
|
|
|
|
|
$
|
8,279
|
|
|
|
(1)
|
Includes co-pay mitigation and voucher rebates.
|
(in thousands)
|
Six months ended June 30, 2017
|
|
Percent of gross
Auryxia product sales |
|
Six months ended June 30, 2016
|
|
Percent of gross
Auryxia product sales |
||||||
Gross Auryxia product sales
|
$
|
43,983
|
|
|
|
|
$
|
21,185
|
|
|
|
||
Less provision for product sales allowances and accruals
|
|
|
|
|
|
|
|
||||||
Trade allowances
|
4,228
|
|
|
9
|
%
|
|
2,701
|
|
|
13
|
%
|
||
Rebates, chargebacks and discounts
|
14,114
|
|
|
32
|
%
|
|
4,221
|
|
|
20
|
%
|
||
Product returns
|
278
|
|
|
1
|
%
|
|
—
|
|
|
—
|
|
||
Other incentives
(1)
|
742
|
|
|
2
|
%
|
|
368
|
|
|
1
|
%
|
||
Total
|
19,362
|
|
|
44
|
%
|
|
7,290
|
|
|
34
|
%
|
||
Net U.S. Auryxia product sales
|
$
|
24,621
|
|
|
|
|
$
|
13,895
|
|
|
|
(1)
|
Includes co-pay mitigation and voucher rebates.
|
|
KERYX BIOPHARMACEUTICALS, INC.
|
||
|
|
|
|
Date: July 27, 2017
|
By:
|
|
/s/ Scott A. Holmes
|
|
|
|
Scott A. Holmes
Chief Financial Officer
|
|
|
|
Principal Financial and Accounting Officer
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated December 17, 2003, and the Amendment thereto, dated June 18, 2004, filed as Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004, filed on August 12, 2004 (File No. 000-30929), and incorporated herein by reference.
|
|
|
|
3.2
|
|
Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated July 24, 2007, filed as Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed on August 9, 2007 (File No. 000-30929), and incorporated herein by reference.
|
|
|
|
3.3
|
|
Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated June 18, 2013, filed as Exhibit 3.4 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, filed on August 2, 2013 (File No. 000-30929), and incorporated herein by reference.
|
|
|
|
3.4
|
|
Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated May 25, 2016, filed as Exhibit 3.4 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed on August 5, 2016 (File No. 000-30929), and incorporated herein by reference.
|
|
|
|
3.5
|
|
Certificate of Validation of the filing and effectiveness of the Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated June 13, 2017.
|
|
|
|
3.6
|
|
Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated June 13, 2017.
|
|
|
|
10.1
|
|
First Supplemental Indenture, dated as of April 10, 2017, by and among Keryx Biopharmaceuticals, Inc., The Bank of New York Mellon Trust Company, N.A. and the note holder signatory thereto, to the Indenture, dated as of October 15, 2015, filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 10, 2017 (File No. 000-30929), and incorporated herein by reference.
|
|
|
|
31.1
|
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated July 27, 2017.
|
|
|
|
31.2
|
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated July 27, 2017.
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated July 27, 2017.
|
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated July 27, 2017.
|
|
|
|
101
|
|
Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Notes to Condensed Consolidated Financial Statements.
|
1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart |
1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions